Soligenix announces investor webcast event: u.s. commercialization of sgx301 in the treatment of cutaneous t-cell lymphoma

Princeton, n.j., jan. 19, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be...
SNGX Ratings Summary
SNGX Quant Ranking